BofA analyst Tazeen Ahmad upgraded Rhythm Pharmaceuticals to Buy from Neutral.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RYTM:
- Rhythm Pharmaceuticals to submit IND for RM-718 by year-end
- Rhythm Pharmaceuticals announces near-term milestones
- Rhythm Pharmaceuticals expects cash to fund operations into 2025
- Rhythm Pharmaceuticals reports Q2 EPS (82c), consensus (79c)
- Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update